A study led by University of Michigan School of Public Health and Rogel Cancer Center researchers will describe and quantify the impact of known and suspected environmental exposures on cancer risk.
Denis Guttridge and Michael Ostrowski of MUSC Hollings Cancer Center and Teresa Zimmers of Indiana University were awarded a $9.7 million, five-year NCI program project grant for their research on the biology behind cachexia.
The Icahn School of Medicine at Mount Sinai has received a $4 million, five-year P30 grant from NIH and the National Institute of Arthritis and Musculoskeletal and Skin Diseases to establish a Skin Biology and Diseases Resource-based Center.
The Commission on Cancer launched a year-long campaign to celebrate its 100-year anniversary following an announcement on Oct. 20 at the CoC Plenary Session.
On behalf of the nation’s radiation oncologists, the American Society for Radiation Oncology expressed strong support for Wednesday’s Senate introduction of bipartisan federal legislation that would rein in restrictive prior authorization practices delaying patient access to critical cancer treatments.
The American Association for Cancer Research sent a letter to CDC director Rochelle Walensky encouraging the agency to recommend booster shots of the various COVID-19 vaccines for caregivers and other people who share a home with cancer patients.
The American Association for Cancer Research launched two career development awards to further diversity, equity, and inclusion in cancer research: one for basic, translational, or population sciences research, and the other for clinical cancer research.
In the field of radiation oncology there is currently tremendous excitement about the delivery of radiation at much higher dose rates than typically used clinically.
A single, high priming dose of tremelimumab added to Imfinzi (durvalumab) demonstrated a statistically significant and clinically meaningful overall survival benefit versus Nexavar (sorafenib) as a first-line treatment for patients with unresectable hepatocellular carcinoma who had not received prior systemic therapy and were not eligible for localized treatment.
The phase III EMERALD study found that when used as a monotherapy for the treatment of ER+/HER2- advanced or metastatic breast cancer, elacestrant significantly improved progression-free survival in the overall population and in patients with tumors harboring estrogen receptor 1 mutations, compared to the standard of care.
